Analyst Reco. Akero Therapeutics, Inc.

Equities

AKRO

US00973Y1082

Real-time Estimate Cboe BZX Other stock markets 02:37:26 2024-05-28 pm EDT			5-day change	1st Jan Change
19 ^USD	+3.71%		-6.18%	-18.67%

May. 15	Evercore ISI Adjusts Price Target on Akero Therapeutics to $38 From $50, Maintains Outperform Rating	MT
May. 10	Akero Therapeutics' Q1 Net Loss Widens; Cash Expected to Fund Operations Into H2 2027	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Evercore ISI Adjusts Price Target on Akero Therapeutics to $38 From $50, Maintains Outperform Rating	May. 15	MT
UBS Adjusts Akero Therapeutics Price Target to $42 From $39, Maintains Buy Rating	Mar. 05	MT
HC Wainwright Raises Price Target on Akero Therapeutics to $50 From $43, Maintains Buy Rating	Mar. 05	MT
UBS Adjusts Akero Therapeutics Price Target to $39 From $83, Maintains Buy Rating	23-10-12	MT
Cantor Fitzgerald Cuts Price Target on Akero Therapeutics to $39 From $69, Maintains Overweight Rating	23-10-11	MT
Morgan Stanley Cuts Price Target on Akero Therapeutics to $33 From $70, Maintains Overweight Rating	23-10-11	MT
RBC Cuts Price Target on 89bio to $27 From $34 Amid 'Negative Read-Through' From 'Disappointing' Akero Data; Outperform, Speculative Risk Kept	23-10-11	MT
Cantor Fitzgerald Initiates Akero Therapeutics at Overweight With $69 Price Target	23-09-19	MT
Evercore ISI Raises Price Target on Akero Therapeutics to $60 From $50, Maintains Outperform Rating	23-09-13	MT
UBS Initiates Coverage on Akero Therapeutics With Buy Rating, $83 Price Target	23-08-28	MT
Health Care Down on Rotation to Rate-Sensitive Sectors -- Health Care Roundup	23-07-07	DJ
Morgan Stanley Raises Price Target on Akero Therapeutics to $70 From $65, Maintains Overweight Rating	23-06-12	MT
HC Wainwright Adjusts Price Target on Akero Therapeutics to $64 From $62, Keeps Buy Rating	23-06-07	MT
Canaccord Genuity Adjusts Price Target on Akero Therapeutics to $59 From $58, Maintains Buy Rating	23-05-17	MT
HC Wainwright Adjusts Price Target on Akero Therapeutics to $62 From $64, Maintains Buy Rating	23-05-16	MT
Canaccord Genuity Adjusts Akero Therapeutics Price Target to $58 From $50, Maintains Buy Rating	23-03-20	MT
Morgan Stanley Upgrades Akero Therapeutics to Overweight From Equal Weight, $65 Price Target	23-01-27	MT
Morgan Stanley Adjusts Price Target on Akero Therapeutics to $40 From $30, Maintains Equalweight Rating	22-11-07	MT
HC Wainwright Adjusts Price Target on Akero Therapeutics to $64 From $62, Maintains Buy Rating	22-11-07	MT
Morgan Stanley Raises Price Target on Akero Therapeutics to $30 From $26, Reiterates Equalweight Rating	22-09-14	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Akero Therapeutics, Inc.

Equities

AKRO

US00973Y1082

Analyst Reco.

Filters